Datasheet

生物学的記述

Specificity	SR-2A Antibody [L13G15] detects endogenous levels of total SR-2A protein.
Background	SR‑2A corresponds to the serotonin 2A receptor (5‑HT2A/HTR2A), a class A G protein‑coupled receptor that is widely expressed in cortex, limbic regions, platelets, and peripheral tissues, where it transduces serotonergic signals into phospholipase C activation, intracellular calcium mobilization, and downstream changes in neuronal excitability, synaptic plasticity, and smooth muscle tone. The receptor has the canonical seven transmembrane helical bundle with extracellular loops contributing to ligand binding, an orthosteric site that accommodates serotonin and a broad range of psychoactive agonists and antagonists, and an intracellular face that couples primarily to Gq/11 proteins, enabling 5‑HT2A to link monoamine neurotransmission to phosphoinositide hydrolysis and IP3/DAG second messenger generation. Activation of 5‑HT2A stimulates PLCβ, leading to IP3‑dependent Ca²⁺ release and DAG‑mediated PKC activation, and also engages β‑arrestin–dependent scaffolding and multiple kinase pathways, including ERK, which together regulate gene expression, receptor desensitization, and long‑term changes in neuronal circuits involved in mood, perception, and cognition. Central 5‑HT2A receptors are highly expressed on pyramidal neurons in prefrontal cortex and other associative areas, where they modulate glutamatergic output and participate in stress and danger‑related responses; stress exposure and glucocorticoid signaling upregulate cortical 5‑HT2A expression and function, supporting the idea that this receptor constitutes part of a stress‑response system that adjusts cortical processing under threat. Dysregulated 5‑HT2A signaling in major depression, schizophrenia, and substance use disorders, with atypical antipsychotics and several antidepressants acting as antagonists or inverse agonists at 5‑HT2A, and with hallucinogenic psychedelics functioning as high‑efficacy 5‑HT2A agonists that induce characteristic alterations in perception and self‑processing via cortical network reorganization.

Specificity

SR-2A Antibody [L13G15] detects endogenous levels of total SR-2A protein.

Background

SR‑2A corresponds to the serotonin 2A receptor (5‑HT2A/HTR2A), a class A G protein‑coupled receptor that is widely expressed in cortex, limbic regions, platelets, and peripheral tissues, where it transduces serotonergic signals into phospholipase C activation, intracellular calcium mobilization, and downstream changes in neuronal excitability, synaptic plasticity, and smooth muscle tone. The receptor has the canonical seven transmembrane helical bundle with extracellular loops contributing to ligand binding, an orthosteric site that accommodates serotonin and a broad range of psychoactive agonists and antagonists, and an intracellular face that couples primarily to Gq/11 proteins, enabling 5‑HT2A to link monoamine neurotransmission to phosphoinositide hydrolysis and IP3/DAG second messenger generation. Activation of 5‑HT2A stimulates PLCβ, leading to IP3‑dependent Ca²⁺ release and DAG‑mediated PKC activation, and also engages β‑arrestin–dependent scaffolding and multiple kinase pathways, including ERK, which together regulate gene expression, receptor desensitization, and long‑term changes in neuronal circuits involved in mood, perception, and cognition. Central 5‑HT2A receptors are highly expressed on pyramidal neurons in prefrontal cortex and other associative areas, where they modulate glutamatergic output and participate in stress and danger‑related responses; stress exposure and glucocorticoid signaling upregulate cortical 5‑HT2A expression and function, supporting the idea that this receptor constitutes part of a stress‑response system that adjusts cortical processing under threat. Dysregulated 5‑HT2A signaling in major depression, schizophrenia, and substance use disorders, with atypical antipsychotics and several antidepressants acting as antagonists or inverse agonists at 5‑HT2A, and with hallucinogenic psychedelics functioning as high‑efficacy 5‑HT2A agonists that induce characteristic alterations in perception and self‑processing via cortical network reorganization.

使用情報

Application

WB, IP, IHC, IF, ELISA

Dilution

WB	IP	IHC	IF
1:100-1:1000	1:100-1:200	1:50-1:500	1:50-1:500

Reactivity

Mouse, Rat, Human

Source

Mouse Monoclonal Antibody

MW

55 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

プロトコール

References

https://pubmed.ncbi.nlm.nih.gov/26500553/
https://pubmed.ncbi.nlm.nih.gov/21204452/

SR-2A Antibody [L13G15]

生物学的記述

使用情報

References

Application Data